Compare Autodesk Inc (ADSK) vs AstraZeneca plc (AZN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Autodesk Inc vs AstraZeneca plc — how do they compare? Autodesk Inc trades at $208.79 (market cap $44.84B), while AstraZeneca plc trades at $189.85 (market cap $294.08B). The key difference: AstraZeneca plc is far larger — about 6.6× Autodesk Inc's market cap, and AstraZeneca plc pays a 1.64% dividend while Autodesk Inc pays none. Which is the better fit depends on your goals.
| ADSK | AZN | |
|---|---|---|
Market Cap | $44.84B | $294.08B |
Sector | Technology | Health |
52-Week High | $326.79 | $209.48 |
52-Week Low | $187.72 | $137.44 |
Enterprise Value | $44.64B | $320.32B |
Dividend Yield | — | 1.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Autodesk (ADSK) trades at $212.38, up 2.36% today, with strong fundamentals including 91.14% gross margins and consistent earnings beats. The stock shows bullish technical signals near resistance at $213, supported by positive analyst sentiment and strategic AI investments. Recent news highlights the MaintainX acquisition and AWS partnership, expanding the company's market reach.
Outlook remains positive with a consensus price target of $308.86, though risks include high valuation multiples and competitive pressures. Earnings growth and AI integration present opportunities, but investors should monitor execution risks and market volatility.
AstraZeneca (AZN) trades at $193.12, down 1.04% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, marking a 17.4% profit margin. Recent news highlights strategic collaborations and regulatory approvals for key drugs like Enhertu, reinforcing growth prospects.
AZN presents a favorable outlook with robust earnings growth and a solid pipeline, though valuation multiples like a P/E of 28.64 suggest premium pricing. Risks include competitive pressures and trial outcomes, but analyst consensus leans bullish with 47.5% buy ratings. Institutional interest remains high, supporting potential upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Autodesk Inc
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
